Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

被引：0
|
作者：
le Coutre, Philipp D. [1 ]
Giles, Francis [2 ]
Hochhaus, Andreas [3 ]
Apperley, Jane F. [4 ]
Ossenkoppele, Gert [5 ]
Haque, Ariful [6 ]
Gallagher, Neil J. [7 ]
Baccarani, Michele [8 ]
Cortes, Jorge [9 ]
Kantarjian, Hagop M. [9 ]
机构：
[1] Humboldt Univ, Dept Hematol & Oncol, Charite, Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, CTRC, Inst Drug Dev, San Antonio, TX 78229 USA
[3] Univ Heidelberg, Fak Med, D-6800 Mannheim, Germany
[4] Hammersmith Hosp, Dept Hematol, London, England
[5] Vrije Univ Amsterdam, Med Ctr, Dept Hematol Br 2, Amsterdam, Netherlands
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Novartis Pharma AG, Oncol, Basel, Switzerland
[8] Inst Hematol & Med OncologySeragnoli, Bologna, Italy
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1108 / 1109
页数：2
相关论文
共 50 条
  • [31] Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005)
    Guilhot, Francoi
    Apperley, Jane F.
    Kim, Dong-Wook
    Kosti, Gianantonio
    Yuan, Xiaobin
    Van Tomout, Jan M. A.
    Gutzon, Felix T.
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [32] Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
    Cortes, Jorge E.
    Hochhaus, Andreas
    le Coutre, Philipp D.
    Rosti, Gianantonio
    Pinilla-Ibarz, Javier
    Jabbour, Elias
    Gillis, Kathryn
    Woodman, Richard C.
    Blakesley, Rick E.
    Giles, Francis J.
    Kantarjian, Hagop M.
    Baccarani, Michele
    BLOOD, 2011, 117 (21) : 5600 - 5606
  • [33] Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Burton, Elizabeth M.
    Trinh, Long Xuan
    Ferrajoli, Alessandra
    Jabbour, Elias
    Kadia, Tapan
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1614 - 1615
  • [34] Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-a (IFN) Refractoriness/Intolerance.
    Kantarjian, Hagop M.
    Sawyers, Charles
    Hochhaus, Andreas
    Schiffer, Charles A.
    Guilhot, Francois
    Niederwieser, Dietger W.
    Gambacorti, Carlo
    Stone, Richard M.
    Fischer, Thomas
    Goldman, John
    Krahnke, T.
    Mone, M.
    Talpaz, Moshe
    Druker, Brian J.
    BLOOD, 2006, 108 (11) : 130A - 131A
  • [35] Phase II study of decitabine in combination with imatinib mesylate in patients with accelerated (AP) or blastic phase (BP) of chronic myeloid leukemia (CML).
    Oki, Y
    Kantarjian, HM
    O'Brien, S
    Verstovsek, S
    Gharibyan, V
    Cortes, J
    Morris, GM
    Garcia-Manero, G
    Issa, JP
    BLOOD, 2005, 106 (11) : 320A - 320A
  • [36] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    Kantarjian, Hagop M.
    Shah, Neil P.
    Cortes, Jorge E.
    Baccarani, Michele
    Agarwal, Mohan B.
    Soledad Undurraga, Maria
    Wang, Jianxiang
    Kassack Ipina, Juan Julio
    Kim, Dong-Wook
    Ogura, Michinori
    Pavlovsky, Carolina
    Junghanss, Christian
    Milone, Jorge H.
    Nicolini, Franck E.
    Robak, Tadeusz
    Van Droogenbroeck, Jan
    Vellenga, Edo
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Hochhaus, Andreas
    BLOOD, 2012, 119 (05) : 1123 - 1129
  • [37] Survival advantage for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) treated with imatinib.
    Cortes, J
    Talpaz, M
    O'Brien, S
    Garcia-Manero, G
    Ravandi-Kashami, F
    Giles, F
    Faderl, S
    Wierda, W
    Shan, JQ
    Rios, MB
    Kantaijian, H
    BLOOD, 2004, 104 (11) : 287A - 288A
  • [38] Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study
    Huang, Xiaojun
    Jiang, Qian
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    Wang, Jianxiang
    BLOOD, 2016, 128 (22)
  • [39] Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)
    Mauro, M. J.
    Baccarani, M.
    Cervantes, F.
    Lipton, J. H.
    Matloub, Y.
    Sinha, R.
    Stone, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Homoharringtonine (HHT) plus cytarabine (Ara-C) for chronic myeloid leukemia in accelerated phase (CML-AP).
    Maloisel, F
    De Sarrazin, A
    Fohrer, C
    Rousselot, P
    Maisonneuve, H
    Lucas, P
    Campos, F
    Dufour, P
    Bergerat, JP
    BLOOD, 2001, 98 (11) : 262B - 262B
12345